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ﻡﺪﺨﺘﺴﻳ،ﻑﻭﺮﻌﻣﻱﺪﻳﺭﻭﻱﻮﻴﺣﺩﺎﻀﻣﻮﻫﻦﻴﺗﺎﺘﺳﻼﻴﺳ-ﻢﻨﻴﺒﻴﻣﻹﺍﻥﺇ:ﺚﺤﺒﻟﺍﻑﺪﻫ
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ﻩﺬﻫﻥﺃﻢﻏﺭ،ﻲﺠﺴﻔﻨﺒﻟﺍﻕﻮﻓﻲﻔﻴﻄﻟﺍﺮﻴﻈﻨﺘﻟﺍﻖﻳﺮﻃﻦﻋﺲﻴﻟﻦﻜﻟﻭ،ﺔﻔﻠﺘﺨﻣﺐﻴﻟﺎﺳﺄﺑ
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Objective: Imipenemecilastatin is a well-established
broad-spectrum intravenous antibiotic used for the
treatment of life-threatening infections worldwide. The
preparation has been studied by various methods but not
by ultraviolet (UV) spectroscopy, although this tech-
nique remains one of the simplest, most accurate and
precise validated quality control laboratory methods.
The aim of this study was to validate a method for
separating the intercalating peaks of the UV spectra of
imipenem and cilastatin and to compare the purity and
quantities of these two active ingredients in different
marketed brands. No previous studies have been con-
ducted to compare the generic product (Cilanem) with
the original (Tienam).
Methods: First-order derivative UV spectrophotometry
was used to separate the intercalating peaks of imipenem
and cilastatin by measuring absorbance at 243 nm and
300 nm, respectively.
Results: Cilanem had better physical characteristics and
a higher cilastatin concentration, while the brand product
Tienam contained a higher concentration of imipenem.
Conclusion: The generic product Cilanem is at least
non-inferior to the brand product Tienam.
Keywords: Cilanem; Imipenemecilastatin; Tienam; UV
assay
 2014 Taibah University. Production and hosting by
Elsevier Ltd. All rights reserved.
O.S. Tabbouche and I. Soukkariyyeh 179IntroductionFigure 2: Structural formula of cilastatin.Imipenem (N-formimidoylthienamycin monohydrate) is
an off-white, non-hygroscopic crystalline derivative of thie-
namycin with the empirical formula C12H17N3O4S$H2O and
a relative molecular mass of 317.37 g. Its structural formula
is shown in Figure 1.1,2 Cilastatin sodium is an off-white to
yellowish-white, hygroscopic, amorphous compound, which
is the sodium salt of a derivatized heptenoic acid. It has the
empirical formula C16H25N2O5SNa and a relative molecular
mass of 380.43 g. Its structural formula is shown in
Figure 2.1,2
Imipenemwas the first carbapenem to be developed,with a
broad spectrum of activity against resistant Gram-positive,
Gram-negative and anaerobic bacteria. Since it was mar-
keted in the 1980s, it has played a central role in the treatment
of severe community- andhospital-acquired infections caused
by multi-drug-resistant microorganisms including Pseudo-
monas aeruginosa and b-lactamase-producing bacteria, such
as penicillins and cephalosporins.5 As the mechanism of
action of imipenem is similar to that of penicillins and
cephalosporins, it is a potent inhibitor of bacterial cell wall
synthesis and exerts a bactericidal effect against all sensitive
microorganisms. Imipenem is rapidly degraded by the renal
enzyme dehydropeptidase I; therefore, an inhibitor of this
enzyme, cilastatin, was added to the formulation to prevent
renal degradation of imipenem and prolong its action.6,7
As there is no Government quality control laboratory in
Lebanon, many drugs obtain official approval for intro-
duction onto the Lebanese market without being subjected to
robust pharmaceutical quality control testing. Much greater
effort is required to ensure the quality, effectiveness and
safety of most of the drugs currently available in Lebanon.
The clinical efficacy and the susceptibility and resistance
of bacteria to the imipenemecilastatin formulation have been
widely studied; however, ultraviolet (UV) spectroscopy, one
of the simplest, most accurate and precise validated quality
control laboratory methods, has not been used for pharma-
ceutical quality control for a long time. The main objective of
our study was to compare the quality of the two brands of
imipenemecilastatin present on the Lebanese market.
To avoid interference between the peaks of imipenem and
cilastatin, which intercalate at 250e350 nm, we combined
zero-order with first-order derivative UV spectroscopy.8
Published studies and international pharmacopaeia have
validated use of the maximum absorbance wavelengths
243 nm and 300 nm for the assay of cilastatin and
imipenem, respectively.1e4 Imipenem alone shows peak
absorbance at 300 nm, while cilastatin alone does not
absorb UV light above 270 nm. At a wavelength ofFigure 1: Structural formula of imipenem.243 nm, imipenem shows minimum UV absorbance in the
zero-order derivative and a zero trough amplitude in the
first-order derivative.
Materials and Methods
Experimental
All experiments were conducted on a Genesys 10S UVe
Vis spectrophotometer (Thermo Scientific) with 1-cm
quartz cuvettes (Hellma Analytics, Germany).
The samples were donated by MSD Inc. and Ranbaxy
Scientific in Lebanon. The two products were Tienam
(MSD, Netherlands, batch no. 2048000) and Cilanem
(Ranbaxy, India, batch no. 2233459).
The formulations, containing a powder equivalent to
500 mg imipenem monohydrate and 500 mg cilastatin so-
dium, were diluted in 100 ml of distilled water to obtain stock
solutions of 5 mg/ml for each compound. Seven dilutions
were prepared in distilled water: 5, 10, 15, 20, 25, 30 and
40 mg/ml.
UV spectrophotometry
Imipenem was assayed at 300 nm and cilastatin at 243 nm.
Standard slopes (Figures 3 and 4) were constructed with the
seven concentrations of each product. Each sample was
tested in triplicate throughout the study.
The concentrations of active ingredients were calculated
from the equation for the standard slope, y ¼ f(x), and the
percentages were calculated from % ¼ 100  (calculated
concentration)/(theoretical concentration) with Tienam as
the reference product (100%).Figure 3: Standard slope for imipenem at 300 nm for both
products.
Figure 4: Standard slope for cilastatin at 243 nm for both
products.
Comparison of imipenemecilastatin formulations180Results
Appearance: All the vials of Tienam tested had powder
caked onto the walls, with considerable amounts of
powder stuck to the edges, a problem that was not
encountered with Cilanem. The caking may be due to
the manufacturing process, from excess humidity inside
the vial or the quality of the glass or seal.
Purity: The two products showed similar purity, with
peak UV absorbance at the same wavelength.
Solubility: Both products were highly soluble in water.
The reconstitution time was 65 s for Tienam and 87 s for
Cilanem.Table 1: Quantification of imipenem at 300 nm (Y[ 0.011X D 0.0
Concentration (mg/ml) A Tienam X Tienam %
5 0.087 5 10
10 0.163 10 10
15 0.221 15 10
20 0.286 20 10
25 0.336 25 10
30 0.399 30 10
40 0.505 40 10
Average
A, average absorbance value; X, calculated concentration (mg/ml).
Table 2: Quantification of cilastatin at 243 nm (Y[ 0.009XD 0.0
Concentration (mg/ml) A Tienam X Tienam %
5 0.068 5 10
10 0.109 10 10
15 0.148 15 10
20 0.201 20 10
25 0.235 25 10
30 0.285 30 10
40 0.39 40 10
Average
A, average absorbance value; X, calculated concentration (mg/ml).The quantities of imipenem and cilastatin in each product
were determined at 243 nm and 300 nm, respectively. The
average absorbance values are shown in Tables 1 and 2, with
calculated concentrations. The average percentages of the
two active ingredients were 98.8% imipenem and 109.0%
cilastatin in Cilanem. The quantitative assays showed that
Tienam contains slightly more imipenem, while Cilanem
contains slightly more cilastatin. The two products showed
similar linearity at different concentrations, which was
within the range 5e40 mg/ml.
Absorbance scanning at wavelengths of 200e350 nm is
shown in Figure 5. First-order derivatives were determined
at the same wavelengths to remove interference between the
two active ingredients (Figure 6). The UV spectrum shows
absorbance values over wavelengths 1 nm apart, ranging
from 200 nm to 350 nm. Zero- and first-order scanning
scanning curves showed that the two products have similar
spectral pathways at all wavelengths. In the zero-order
derivative curve, both products showed one peak at
300 nm, which reflects the purity of imipenem. The differ-
ence in absorbance values was not significant. The highest
peak was observed with Tienam. The first-order derivative
scanning curve showed zero trough amplitude at 300 nm
for both products, which corresponds to the peak on the
zero-order scanning curve, and two peaks at lmax, which
correspond to the inflections of the zero-order scanning
curve.Discussion
As our present study shows, first order derivative spec-
troscopy is of importance in the assay of Imipenem/4. r2 [ 0.997).
Tienam A Cilanem X Cilanem % Cilanem
0% 0.079 4.54 90.8%
0% 0.149 9.14 91.4%
0% 0.238 16.15 107.7%
0% 0.2675 18.70 93.5%
0% 0.36 26.78 107.1%
0% 0.42 31.57 105.2%
0% 0.484 38.33 95.8%
98.8%
31. r2 [ 0.996).
Tienam A Cilanem X Cilanem % Cilanem
0% 0.078 5.73 114.6%
0% 0.127 11.65 116.5%
0% 0.1575 15.96 106.4%
0% 0.203 20.19 101.0%
0% 0.255 27.12 108.5%
0% 0.316 33.26 110.9%
0% 0.411 42.15 105.4%
109.0%
Figure 5: Zero-order scanning curve at wavelengths of 200e
350 nm for both products; concentration, 15 mg/ml.
Figure 6: First-order scanning curve for both products; concen-
tration, 15 mg/ml.
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spectrograms of the two present APIs.The two products had comparable quality profiles, each
having slight advantages in certain criteria over the other.
The larger amount of cilastatin in Cilanemmay prolong the
duration of action of the imipenem in the formulation.Conclusion
We conclude that the generic formulation Cilanem has
an acceptable, competitive quality profile in comparison with
that of the original product Tienam.Conflict of interest
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